![]() |
||||
|
||||
|
|
||||
Re: Estrogen and breast cancerFrom: Richard Chudacoff, MD (rchudacoff@mylinuxisp.com)Mon Jul 26 10:27:32 2004
Well, if you have a patient without adverse effects to ERT, then there is no concern regarding the therapy. Hence, the risks of the therapy are nil. However, if you do have a patient who develops breast cancer on ERT, then the risk of therapy is very real. I'm not aware of studies in vitro or in vivo that has suggested that estrogen is an initiator of breast cancer, but there are studies that implicate estrogen as a promoter of breast cancer. These cancers do tend to have more E/P receptors; therefore they are more amiable to SERM therapy. Non-estrogen related breast cancer tends not to be as responsive to SERMs. The latter tends to be more aggressive and fatal. Where is the flaw in my logic? No breast cancer: no concern for therapy. Cancer present: concern for therapy. If there is a concern for therapy, is it better to be on ERT or not on ERT. If therapy is not of a concern then the question is moot.
-- Richard Chudacoff, MD
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Sun Nov 2 04:49:17 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.